A decreasing CD4+/CD8+ ratio after one month of treatment with stanazolol in postmenopausal women.
Androgens influence some immunological processes, including the differentiation of T-cells in CD4+ (helpers) or CD8+ (suppressors/cytotoxic) phenotype. In nine postmenopausal osteoporotic women the effect of stanazolol on lymphocyte counts, CD3+ and the immunoregulatory index (CD4+/CD8+) were investigated. In the placebo group, ten postmenopausal osteoporotic women of similar age were included. The means of the investigated indices after stanazolol as compared with the values before treatment were as follows: lymphocyte counts (cells/microL +/- SEM) 2974 +/- 225 versus 2313 +/- 166, CD3+ (%) 54.3 +/- 5.5 versus 70.9 +/- 1.6 (P < 0.05); CD4+/CD8+ ratio 1.8 +/- 0.02 versus 2.5 +/- 0.28 (P < 0.05). The values after placebo as compared with the values before placebo were: 2558 +/- 201 versus 2370 +/- 256, 62.9 +/- 2.1 versus 64.8 +/- 1.7 and 1.6 +/- 0.2 versus 1.6 +/- 0.1 in sequence. The treatment was controlled by the serum stanazolol levels before and after steroid administration (unmeasurable versus 20.8 +/- 3.4 nmol/L, P < 0.01). The good compliance of the therapy was confirmed by a decline of serum LH (U/L; 30.1 +/- 3.1 versus 24.7 +/- 2.8, P = 0.014), FSH (U/L; 108.9 +/- 13.1 versus 93.3 +/- 12.8, P = 0.012) and serum sex hormone binding globulin (SHBG; nmol/L; 53.3 +/- 13.3 versus 11.2 +/- 1.9, P < 0.01). The decline of SHBG indicates a good tissue sensitivity to the androgen. There were no significant differences between hormonal parameters before and after placebo treatment. In conclusion, the immunosuppressive effect of the androgen, stanazolol, was confirmed in the investigated postmenopausal osteoporotic women.(ABSTRACT TRUNCATED AT 250 WORDS)
D045930:Anabolic Agents / Q000627:therapeutic use*; D016516:CD4-CD8 Ratio; D005260:Female; D005640:Follicle Stimulating Hormone / Q000097:blood; D006801:Humans; D007986:Luteinizing Hormone / Q000097:blood; D008875:Middle Aged; D015663:Osteoporosis, Postmenopausal / Q000188:drug therapy* / Q000276:immunology*; D010919:Placebos; D012738:Sex Hormone-Binding Globulin / Q000378:metabolism; D013197:Stanozolol / Q000097:blood / Q000627:therapeutic use*
D045930:Anabolic Agents; D010919:Placebos; D012738:Sex Hormone-Binding Globulin; D013197:Stanozolol; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone